TWI786095B - 用於鑑別復發性或轉移性癌症風險或預測癌症患者預後之方法 - Google Patents

用於鑑別復發性或轉移性癌症風險或預測癌症患者預後之方法 Download PDF

Info

Publication number
TWI786095B
TWI786095B TW107108604A TW107108604A TWI786095B TW I786095 B TWI786095 B TW I786095B TW 107108604 A TW107108604 A TW 107108604A TW 107108604 A TW107108604 A TW 107108604A TW I786095 B TWI786095 B TW I786095B
Authority
TW
Taiwan
Prior art keywords
cancer
circulating tumor
tumor cells
blood sample
individual
Prior art date
Application number
TW107108604A
Other languages
English (en)
Chinese (zh)
Other versions
TW201902534A (zh
Inventor
曾如玉
陳嬿如
李佳螢
武立凡
王信翰
陳瑞麟
陳純誠
Original Assignee
上準微流體股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上準微流體股份有限公司 filed Critical 上準微流體股份有限公司
Publication of TW201902534A publication Critical patent/TW201902534A/zh
Application granted granted Critical
Publication of TWI786095B publication Critical patent/TWI786095B/zh

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
TW107108604A 2017-03-14 2018-03-14 用於鑑別復發性或轉移性癌症風險或預測癌症患者預後之方法 TWI786095B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762471083P 2017-03-14 2017-03-14
US62/471,083 2017-03-14
US201762584634P 2017-11-10 2017-11-10
US62/584,634 2017-11-10

Publications (2)

Publication Number Publication Date
TW201902534A TW201902534A (zh) 2019-01-16
TWI786095B true TWI786095B (zh) 2022-12-11

Family

ID=61868129

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107108604A TWI786095B (zh) 2017-03-14 2018-03-14 用於鑑別復發性或轉移性癌症風險或預測癌症患者預後之方法

Country Status (8)

Country Link
US (1) US20180267046A1 (enExample)
EP (1) EP3376227B1 (enExample)
JP (1) JP2018155752A (enExample)
KR (1) KR20180105091A (enExample)
CN (1) CN108572255B (enExample)
AU (1) AU2018201819A1 (enExample)
CA (1) CA2998065A1 (enExample)
TW (1) TWI786095B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110142068B (zh) * 2019-06-12 2024-02-02 杭州华得森生物技术有限公司 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法
CN111551718A (zh) * 2020-04-20 2020-08-18 山东第一医科大学(山东省医学科学院) 一种检测前列腺癌患者外周血循环肿瘤细胞pd-l1表达的免疫荧光试剂盒及检测方法
CN111562375B (zh) * 2020-04-20 2022-05-06 山东第一医科大学(山东省医学科学院) 一种检测胃癌患者外周血循环肿瘤细胞pd-l1表达的免疫荧光试剂盒及检测方法
TWI874453B (zh) * 2020-09-17 2025-03-01 日商細胞雲股份有限公司 使用末稍血循環腫瘤細胞之解析的癌症治療方法
RU2738563C1 (ru) * 2020-09-18 2020-12-14 Ен Джун Чой Способ прогноза малигнизации и ранней диагностики злокачественных опухолей
CN120559253A (zh) * 2025-05-30 2025-08-29 中国医学科学院肿瘤医院 Pd-l1阳性循环肿瘤细胞在肝癌免疫治疗中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061064A1 (en) * 2014-10-15 2016-04-21 Epic Sciences, Inc. Circulating tumor cell diagnostics for therapy targeting pd-l1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399130A4 (en) * 2009-02-20 2012-06-06 Wayne John Cancer Inst ASSAY OF B7-H3 ANTIBODY-COUPLED BEADS FOR THE ISOLATION AND DETECTION OF CIRCULATING TUMOR CELLS IN THE BODILY FLUIDS OF MELANOMA AND BREAST CANCER PATIENTS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061064A1 (en) * 2014-10-15 2016-04-21 Epic Sciences, Inc. Circulating tumor cell diagnostics for therapy targeting pd-l1

Also Published As

Publication number Publication date
EP3376227C0 (en) 2024-02-21
TW201902534A (zh) 2019-01-16
AU2018201819A1 (en) 2018-10-04
US20180267046A1 (en) 2018-09-20
CN108572255A (zh) 2018-09-25
CN108572255B (zh) 2023-05-16
CA2998065A1 (en) 2018-09-14
KR20180105091A (ko) 2018-09-27
EP3376227A1 (en) 2018-09-19
JP2018155752A (ja) 2018-10-04
EP3376227B1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
TWI786095B (zh) 用於鑑別復發性或轉移性癌症風險或預測癌症患者預後之方法
Cauley et al. Circulating epithelial cells in patients with pancreatic lesions: clinical and pathologic findings
Catenacci et al. Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound
Li et al. Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer
Wang et al. Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in lung cancer
Park et al. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma
US20140113310A9 (en) Cancer detection markers
Jin et al. Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review
Lou et al. Assessment of circulating tumor cells as a predictive biomarker of histology in women with suspected ovarian cancer
US10139412B2 (en) Semaphorin 3A as a diagnostic marker for urothelial cancer
Li et al. Liquid biopsy in lung cancer
Manicone et al. Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer
Croitoru et al. Clonal hematopoiesis and liquid biopsy in gastrointestinal cancers
Jee et al. Midkine concentrations in fine‐needle aspiration of benign and malignant thyroid nodules
Wang et al. Systematic correlation analyses of circulating tumor cells with clinical variables and tumor markers in lung cancer patients
Balic et al. Micrometastasis: detection methods and clinical importance
Poggiana et al. Possible role of circulating tumor cells in early detection of lung cancer
Kim et al. Detection of circulating tumor cells and their potential use as a biomarker for advanced renal cell carcinoma
Cheng et al. Combined detection and subclass characteristics analysis of CTCs and CTECs by SE-iFISH in ovarian cancer
Yang et al. Enhanced prognostic value of combined circulating tumor cells and serum carcinoembryonic antigen in patients with colorectal cancer
JP7237587B2 (ja) マーカー、ヒト精巣上体タンパク質４（ｈｅ４）に基づく肺腺癌の再発を検出する方法および関連する使用
Sonn et al. Detection of circulating tumor cells in patients with non-small cell lung cancer using a size-based platform
Tamminga et al. Investigating CTCs in NSCLC—a reaction to the study of Jia-Wei Wan: a preliminary study on the relationship between circulating tumor cells count and clinical features in patients with non-small cell lung cancer
Liu et al. The value of circulating tumor cells with positive centromere probe 8 in the diagnosis of small pulmonary nodules
Wang et al. RETRACTED ARTICLE: Survivin mRNA-circulating tumor cells are associated with prostate cancer metastasis